Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.

× No keyword cloud information.

10 in total

1. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring EGFR Mutations.

Authors: Yoshihito Kogure; Fumie Shigematsu; Masahide Oki; Hideo Saka
Journal: In Vivo Date: 2018 Sep-Oct Impact factor: 2.155

2. Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.

Authors: Tri Le; Joseph Sailors; Dwight H Oliver; Melissa Mayer; Sharon Hoskin; David E Gerber
Journal: Lung Cancer Date: 2017-01-11 Impact factor: 5.705

3. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.

Authors: D Zheng; X Ye; M Z Zhang; Y Sun; J Y Wang; J Ni; H P Zhang; L Zhang; J Luo; J Zhang; L Tang; B Su; G Chen; G Zhu; Y Gu; J F Xu
Journal: Sci Rep Date: 2016-02-12 Impact factor: 4.379

4. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.

Authors: Yan Zhang; Hui-Min Chen; Yong-Mei Liu; Feng Peng; Min Yu; Wei-Ya Wang; Heng Xu; Yong-Sheng Wang; You Lu
Journal: World J Clin Cases Date: 2019-05-26 Impact factor: 1.337

5. Hyper expression of MTBP may be an adverse signal for the survival of some malignant tumors: A data-based analysis and clinical observation.

Authors: Yantao Mao; Mei Tian; Bo Pan; Qingshan Zhu; Paiyun Li; Hongmei Liu; Weipeng Liu; Ningtao Dai; Lili Yu; Yuan Tian
Journal: Medicine (Baltimore) Date: 2018-08 Impact factor: 1.817

6. Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Authors: Tilak K Sundaresan; Lecia V Sequist; John V Heymach; Gregory J Riely; Pasi A Jänne; Walter H Koch; James P Sullivan; Douglas B Fox; Robert Maher; Alona Muzikansky; Andrew Webb; Hai T Tran; Uma Giri; Martin Fleisher; Helena A Yu; Wen Wei; Bruce E Johnson; Thomas A Barber; John R Walsh; Jeffrey A Engelman; Shannon L Stott; Ravi Kapur; Shyamala Maheswaran; Mehmet Toner; Daniel A Haber
Journal: Clin Cancer Res Date: 2015-10-07 Impact factor: 12.531

7. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.

Authors: Hidenobu Ishii; Koichi Azuma; Kazuko Sakai; Akihiko Kawahara; Kazuhiko Yamada; Takaaki Tokito; Isamu Okamoto; Kazuto Nishio; Tomoaki Hoshino
Journal: Oncotarget Date: 2015-10-13

8. Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.

Authors: Chang Gon Kim; Hyo Sup Shim; Min Hee Hong; Yoon Jin Cha; Su Jin Heo; Hyung Soon Park; Jee Hung Kim; Jin Gu Lee; Chang Young Lee; Byoung Chul Cho; Hye Ryun Kim
Journal: Oncotarget Date: 2017-05-10

9. Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Authors: Teresa Morán; Eudald Felip; Joaquim Bosch-Barrera; Itziar de Aguirre; Jose Luis Ramirez; Carles Mesia; Enric Carcereny; Diana Roa; Elia Sais; Yolanda García; Remei Blanco; Silvia Sanchez; Claudia Rosa Villacorta; Cristina Queralt; Jose María Velarde; Rafael Rosell
Journal: Oncotarget Date: 2018-06-05

Review 10. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.

Authors: Chennianci Zhu; Weihao Zhuang; Limin Chen; Wenyu Yang; Wen-Bin Ou
Journal: Transl Lung Cancer Res Date: 2020-02

10 in total